Highlights
- •First-in-human Phase I study of toripalimab in patients with advanced malignant tumor.
- •Toripalimab was well tolerated up to 10mg/kg Q2W without DLT.
- •25.0% (3/12) ORR and 91.7% (11/12) DCR in alveolar soft part sarcoma patients.
- •90.9% (10/11) ORR and 90.9% (10/11) DCR in lymphoma patients.
- •Median DOR 21.5 months for all responding patients.
Abstract
Purpose
This is a first-in-human phase I study investigating the safety and efficacy of toripalimab,
a humanized monoclonal antibody against the programmed cell death-1 (PD-1) receptor,
in Chinese patients with advanced or recurrent malignant tumor refractory to standard
treatment.
Patients and methods
During dose escalation, patients received a single-dose intravenous infusion of toripalimab
for 56 days followed by multidose infusions every two weeks. The planned dosing groups
were 1, 3 and 10 mg/kg. During dose expansion, patients received toripalimab every
two weeks. Clinical response was evaluated by investigators every 6 weeks.
Results
Thirty-three patients were enrolled, including 12 patients with alveolar soft part
sarcoma (ASPS), seven with non–small-cell lung cancer and 11 with lymphoma. Patients
were heavily pretreated with a median of 3 prior lines of systemic treatments. Toripalimab
was well tolerated without dose-limiting toxicity. All patients experienced treatment-related
adverse events. Grade 3 and above treatment-related adverse events occurred in six
(18.2%) patients. Among 22 solid tumors, the objective response rate (ORR) was 22.7%
per RECIST v1.1. The ORR was 90.9% in 11 lymphoma patients per IWG 2007. The median
duration of response was 21.5 months. The median progression-free survival was 5.7
months for solid tumors and 8.3 months for lymphomas. The median OS was not reached
for all patients and the lymphoma subgroups. The median OS was 34.7 months for patients
with ASPS.
Conclusion
Toripalimab was well tolerated up to 10 mg/kg Q2W without dose-limiting toxicity and
showed promising and durable antitumour activities in patients with ASPS and lymphoma,
who were heavily pretreated.
Clinical trial information
ClinicalTrials.gov Identifier: NCT02836834.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Fundamental mechanisms of immune checkpoint blockade therapy.Canc Discov. 2018; 8: 1069-1086
- The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Canc. 2012; 12: 252-264
- Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.N Engl J Med. 2015; 373: 123-135
- Pembrolizumab for the treatment of non-small-cell lung cancer.N Engl J Med. 2015; 372: 2018-2028
- Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.N Engl J Med. 2015; 373: 1627-1639
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006).Lancet. 2017; 390: 1853-1862
- Pembrolizumab versus ipilimumab in advanced melanoma.N Engl J Med. 2015; 372: 2521-2532
- Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N Engl J Med. 2015; 373: 23-34
- Nivolumab in previously untreated melanoma without BRAF mutation.N Engl J Med. 2015; 372: 320-330
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 1493-1501
- Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study.Cancer. 2017; 123: 3285-3290
- Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody.Acta Pharmacol Sin. 2017; 38: 710-718
- Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.mAbs. 2019; 11: 681-690
- Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health. vol. 4. National Cancer Institute, 2009
- Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial.J Clin Oncol. 2018; 36: 1428-1439
- Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma.J Clin Oncol. 2017; 35: 2125-2132
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.Blood. 2010; 116: 3268-3277
- Diagnosis, prognosis, and treatment of alveolar soft-Part Sarcoma: areview.JAMA Oncol. 2019; 5: 254-260
- PD-L1 expression as a predictive biomarker in cancer immunotherapy.Mol Canc Therapeut. 2015; 14: 847-856
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.Lancet Oncol. 2018; 19: 405-415
- Lenvatinib + pembrolizumab in patients with renal cell carcinoma: updated results.J Clin Oncol. 2018; 36: 4560
- Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.Lancet Oncol. 2019; 20: 711-718
- Systemic therapy for advanced hepatocellular carcinoma in an evolving landscape.Curr Treat Options Oncol. 2019; 20: 3
Article info
Publication history
Published online: March 27, 2020
Accepted:
January 21,
2020
Received:
January 16,
2020
Identification
Copyright
© 2020 Elsevier Ltd. All rights reserved.
